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A 51-year-old man, with a history of severe COPD and bilateral pneumothorax, who was under treatment for pulmonary tubercu-
losis due to mycobacterium avium, was admitted due to high-grade fever, weight loss, cough, and production of purulent sputum,
for almost one month without any special improvement despite adequate antibiotics treatment in outpatient setting. A CT scan
revealed multiple consolidations, ﬁbrosis, scaring, and cavitary lesions in both upper lobes with newly shadows which were fungus
balls inside them. Aspergillus ﬂavius was isolated in three sputum samples, a diagnosis of chronic cavitary pulmonary aspergillosis
was made, and treatment with intravenous amphotericin B was started. An initially clinical improvement was noted, and a ﬁrst
episode of minor hemoptysis was treated with conservative measures. Unfortunately a second major episode of hemoptysis
occurred and he died almost immediately. Aspergilloma is deﬁned as the presence of a fungus ball inside a preexisting pulmonary
cavity or dilated airway and is one of the clinical conditions associated with the clinical spectrum of pulmonary colonization.
Tuberculosis is the most common underling disease. Hemoptysis is the most common symptom. Antifungal antibiotics, surgical
interventions, bronchial arteries embolization, and intracavity infusion of antibiotics have been proposed without always adequate
suﬃciency.
1.Introduction
Aspergillus spp are ubiquitous soil-dwelling microorganisms
found in dust, foods, organic materials, compost, spices, and
rotted plants, and they colonize human respiratory system
primary through airborne spore’s inhalation. Although there
are almost 200 known species of Aspergillus, only a few pro-
voke human disease. Aspergillus fumigates and aspergillus
niger are the most encountered, others like aspergillus ﬂa-
vius, aspergillus clavatus, aspergillus niveus, aspergillus ter-
reus, or aspergillus nidulans are also to be responsible in
some cases [1, 2].
2. Case Presentation
A 50-year-old male, smoker (50p/y), with a history of alco-
holism, severe COPD, bilateral pneumothorax, and tubercu-
losis due to mycobacterium avium infection, was admitted
in our department eight months after antituberculosis treat-
mentinitializationduetoone-monthperiodofhighfever,up
to 39.6◦C, loss of weight, almost 5kgr, and productive cough
with purulent sputum (Figures 1 and 2). Despite adequate
treatmentwithantibiotics,inoutpatientsetting,heremained
with no clinical improvement. Routine laboratory tests on
admission revealed increased erythrocyte sedimentation rate
(ESR = 134mm/hr) and C-reactive protein (CRP = 112mg/
dL). A chest X-ray demonstrated cavitations, consolidation,
and ﬁbrosis at both upper lobes. Serologic tests for hepatitis
A, B, C, D, and human immunodeﬁciency virus did not
reveal any abnormality. Broad spectrum antibiotics were ini-
tializedduringhishospitalizationwithoutanyimprovement.
Finally in three diﬀerent sputum samples Aspergillus ﬂavius
was isolated and, a CT scan demonstrated cavitary lesions
with shadows, probably due to fungus contamination inside
them, especially in the upper left lobe (Figures 3 and 4).2 Case Reports in Infectious Diseases
13:36:03.94
TP −3.0
SEQ 12
C
W
ea/e3
kV 120
mA 13
TI 1.0
GT 0.0
SL 2.0
385 4/-43
AB50 SM
121 020
150.0
−450
10cm
R
Figure 1: Two years before his admission he was presented with
dyspnea on exception, and on CT imaging emphysema was the
main evidence.
These facts established a diagnosis of chronic cavitary pul-
monary aspergillosis. Treatment with amphotericin B pro-
vided an initial clinical improvement but eleven days after a
ﬁrst episode of mild hemoptysis occurred and was controlled
with conservative measures. Eighteen days after treatment
initialization a second episode of hemoptysis occurred and,
although he was intubated immediately, his cardiorespira-
tory system collapsed and he died.
3. Discussion
Aspergilloma is deﬁned as the presence of fungus balls inside
preexisting cavities or dilated airways and is one form of
pulmonary pathology due to the inhabitation of Aspergillus
spp into the respiratory system [1]. This fungal ball histology
consists of fungal mycelia, ﬁbrin, mucus, inﬂammatory cells,
and tissue debris [4]. A preexisting pulmonary cavity is
a key element. Tuberculosis is the most frequent cause of
the formation of such condition [1–3, 5, 6]. Sarcoidosis,
emphysema, bronchial cysts or bulla, brochiectasis, ankylos-
ing spondylitis, neoplasms, pulmonary infraction, and other
infections, even a prior fungal one, have been described to
contribute as well [5, 7–10].
Recently a prior classiﬁcation as simple or convex has
changed to simple and chronic cavitary pulmonary asper-
gillosis. Simple aspergillomas are associated with thick-wall
cysts and little surrounding parenchymal damage whereas
chronic cavitary disease is the more devastating form with
thick walls, multiple cavities, and substantial parenchymal
changes [2].
Althoughsomeaspergillomasremainasymptomatic,and
found as an incidental ﬁnding on chest radiographs, most
became symptomatic. Hemoptysis is the commonest symp-
tom, it occurs to 69% to 83% of all patients, and it ranges
from mild to lifethreatening, with a mortality rate ranging
from 2% to 14% [6, 11–15]. Other symptoms include
fever, malaise, weight loss, productive cough, and clubbing
and could be associated with the underlined disease [1–3].
Hemoptysis is believed to be from bronchial origin, but only
speculations could be done according to the pathophysi-
ological underling mechanisms. It seems that anastomotic
plexus between pulmonary and bronchial arteries around
the damaged parenchyma is a main factor to hemoptysis
occurrence [4].
Diagnosis of aspergilloma is achieved by a combination
of clinical suspicion with radiological, microbiologic, and
serologicﬁndings.Radiological imaging ofaspergillomamay
be diﬃcult in plain radiographs, and chest CT scan is needed
to establish diagnosis. The presence of a mobile intracavity
mass with an air crescent in the periphery with possible
thickening of the adjacent pleura is the main evidence.
Achangeinthepositionofthefungusballwhenthepatientis
rotatedduringscanisaninterestingﬁndingalthoughinmost
cases rather variable [16, 17]. Diﬀerential diagnosis of such
radiographic appearance includes malignancies, abscesses,
hydatid cysts, hematomas, and Wegener granulomatosis,
and in fact any of these conditions may coexist [18, 19].
Sputum examination may contribute to diagnosis revealing
the presence of aspergillus spp although a high possibility
of negative examinations, up to 50% in some reports, may
be present. Serum IgG antibodies are rather helpful, but in
cases of aspergilloma due to species other than Aspergillus
fumigatus or in patients under steroid treatment the results
could be falsely negative [7].
A nonimmunocompromised patient without any symp-
toms usually does not require any treatment [2]. Recent
guidelines originated from Infectious Diseases Society of
America (IDSA) recommend that if the disease progresses or
thepatientdevelopshemoptysistreatmentwithvoriconazole
(6mg/kg IV every 12h for 1 day, followed by 4mg/kg IV
every 12h, oral dosage is 200mg every 12h) or itraconazole
could be used [20]. In our case the alternative use of am-
photericin B (5mg/kg/day IV) achieved a substantial im-
provement without any side eﬀects which always must be
in concern. Surgical interventions included cavernostomy,
segmentectomy, lobectomy, and pneumonectomy, and they
arenotconsideredasﬁrst-linetherapyduetohighmorbidity
and mortality, although they are improving over time. Post-
operative nonfatal complications include prolonged air leak,
empyema, incomplete lung expansion, hemorrhage, wound
infection,chylothorax,andrespiratoryinsuﬃciency[21–30].
Due to the above only in selected patients with low surgical
risk such surgical invasive procedures combined with antibi-
oticsseemreasonableenough.Bronchialarteryembolization
is an eﬀective and safe procedure to control hemoptysis,
but unfortunately high rates of recurrences and mortality
are associated with aspergilloma [31, 32]. Present guidelines
recommend embolization as a short-term treatment bridg-
ing these procedures to more deﬁnite therapy like surgery
[20]. Finally some researchers have proposed CT-guided
intracavitaryinfusionofamphotericinBasacomplementary
therapy in cases of hemoptysis, but the results are still
inconclusive [33, 34].
In conclusion the inhalation of spores and the coloniza-
tion of Aspergillus spp into the respiratory system result inCase Reports in Infectious Diseases 3
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Figure 2: Almost one year prior to his admission he was presented with weight loss, fever, and dyspnea and pulmonary tuberculosis due to
mycobacterium avium infection was diagnosed. One month after a bilateral pneumothorax (arrows) was diagnosed and pleurodesis was
performed.
Figure 3:Onscanogramarathercatastrophicviewisdemonstrated
including cavitary lesions, extensive ﬁbrosis, and consolidation
mainly at the upper lobes.
a wide spectrum of clinical conditions. The presence of pre-
existing cavities is the factor that leads to aspergilloma which
in cases of severe hemoptysis leads to a rather threatening
disease and even death despite adequate treatment. Early
clinical suspicion, diagnosis, and multimodality treatment,
including antifungal antibiotics, surgery, embolization, or
even newer techniques, like intracavitary infusion of antibi-
otics, are nowadays the treatment options for aspergillomas
therapy.
Figure 4: On a CT scan view of the upper lobes cavity lesions are
demonstrated, with new shadows inside them, most probably due
to aspergillus infection.
References
[1] A. O. Soubani and P. H. Chandrasekar, “The clinical spectrum
of pulmonary aspergillosis,” Chest, vol. 121, no. 6, pp. 1988–
1999, 2002.
[ 2 ]B .P .R i s c i l ia n dK .L .W o o d ,“ N o n i n v a s i v ep u l m o n a r ya s p e r -
gillus infections,” Clinics in Chest Medicine,v o l .3 0 ,n o .2 ,p p .
315–335, 2009.4 Case Reports in Infectious Diseases
[3] O. S. Zmeili and A. O. Soubani, “Pulmonary aspergillosis:
a clinical update,” QJM, vol. 100, no. 6, pp. 317–334, 2007.
[4] R. Shah, P. Vaideeswar, and S. Pandit, “Pathology of pul-
monaryaspergillomas,”IndianJournalofPathologyandMicro-
biology, vol. 51, no. 3, pp. 342–345, 2008.
[5] S. Kawamura, S. Maesaki, K. Tomono, T. Tashiro, and S.
Kohno, “Clinical evaluation of 61 patients with pulmonary
aspergilloma,” Internal Medicine, vol. 39, no. 3, pp. 209–212,
2000.
[6] “Aspergilloma and residual tuberculous cavities: the results of
a resurvey,” Tubercle, vol. 51, pp. 227–245, 1970.
[7] P. Raﬀe r t y ,B .A .B i g g s ,G .K .C r o m p t o n ,a n dI .W .B .G r a n t ,
“What happens to patients with pulmonary aspergilloma?
Analysis of 23 cases,” Thorax, vol. 38, no. 8, pp. 579–583, 1983.
[8] S. Hours, H. Nunes, M. Kambouchner et al., “Pulmonary cav-
itary sarcoidosis: clinico-radiologic characteristics and natural
history of a rare form of sarcoidosis,” Medicine, vol. 87, no. 3,
pp. 142–151, 2008.
[9] G. A. Sarosi, P. M. Silberfarb, N. A. Saliba, P. M. Huggin, and
F.E.Tosh,“Aspergillomasoccurringinblastomycoticcavities,”
American Review of Respiratory Disease, vol. 104, no. 4, pp.
581–584, 1971.
[10] S. H. Rosenheim and J. Schwarz, “Cavitary pulmonary cryp-
tococcosis complicated by aspergilloma,” American Review of
Respiratory Disease, vol. 111, no. 4, pp. 549–553, 1975.
[11] J. Jewkes, P. H. Kay, M. Paneth, and K. M. Citron, “Pulmonary
aspergilloma: analysis of prognosis in relation to haemoptysis
and survey of treatment,” Thorax, vol. 38, no. 8, pp. 572–578,
1983.
[12] J. Garvey, P. Crastnopol, D. Weisz, and F. Khan, “The surgical
treatment of pulmonary aspergillomas,” Journal of Thoracic
and Cardiovascular Surgery, vol. 74, no. 4, pp. 542–547, 1977.
[ 1 3 ]R .C .D a l y ,P .C .P a i r o l e r o ,a n dJ .M .P i e h l e r ,“ P u l m o n a r y
aspergilloma. Results of surgical treatment,” J o u r n a lo fT h o -
racic and Cardiovascular Surgery, vol. 92, no. 6, pp. 981–988,
1986.
[14] A.Karas,J.R.Hankins,andS.Attar,“Pulmonaryaspergillosis:
an analysis of 41 patients,” Annals of Thoracic Surgery, vol. 22,
no. 1, pp. 1–7, 1976.
[15] R. A. Glimp and A. S. Bayer, “Pulmonary aspergilloma. Diag-
nostic and therapeutic considerations,” Archives of Internal
Medicine, vol. 143, no. 2, pp. 303–308, 1983.
[16] E. Tuncel, “Pulmonary air meniscus sign,” Respiration, vol. 46,
no. 1, pp. 139–144, 1984.
[17] C. M. Roberts, K. M. Citron, and B. Strickland, “Intrathoracic
aspergilloma: role of CT in diagnosis and treatment,” Radiol-
ogy, vol. 165, no. 1, pp. 123–128, 1987.
[18] D. L. T. Huong, B. Wechsler, J. P. Chamuzeau, A. Bisson, and
P. Godeau, “Pulmonary aspergilloma complicating Wegener’s
granulomatosis,” Scandinavian Journal of Rheumatology, vol.
24, no. 4, p. 260, 1995.
[19] S. Bandoh, J. Fujita, Y. Fukunaga et al., “Cavitary lung cancer
with an aspergilloma-like shadow,” Lung Cancer, vol. 26, no. 3,
pp. 195–198, 1999.
[20] T. J. Walsh, E. J. Anaissie, D. W. Denning et al., “Treatment
of aspergillosis: clinical practice guidelines of the infectious
diseases society of America,” Clinical Infectious Diseases, vol.
46, no. 3, pp. 327–360, 2008.
[21] A. Brik, A. M. Salem, A. R. Kamal et al., “Surgical outcome of
pulmonary aspergilloma,” European Journal of Cardio-thoracic
Surgery, vol. 34, no. 4, pp. 882–885, 2008.
[ 2 2 ]K .O k u b o ,M .K o b a y a s h i ,H .M o r i k a w a ,E .H a y a t s u ,a n dY .
Ueno, “Favorable acute and long-term outcomes after the
resection of pulmonary aspergillomas,” Thoracic and Cardio-
vascular Surgeon, vol. 55, no. 2, pp. 108–111, 2007.
[23] A. Chatzimichalis, G. Massard, R. Kessler et al., “Bron-
chopulmonaryaspergilloma:areappraisal,” AnnalsofThoracic
Surgery, vol. 65, no. 4, pp. 927–929, 1998.
[24] S. Endo, S. I. Otani, Y. Tezuka et al., “Predictors of postop-
erative complications after radical resection for pulmonary
aspergillosis,” Surgery Today, vol. 36, no. 6, pp. 499–503, 2006.
[25] Y. Shiraishi, N. Katsuragi, Y. Nakajima, M. Hashizume, N.
Takahashi, and Y. Miyasaka, “Pneumonectomy for complex
aspergilloma: is it still dangerous?” European Journal of Car-
dio-thoracic Surgery, vol. 29, no. 1, pp. 9–13, 2006.
[26] Y. T. Kim, M. C. Kang, S. W. Sung, and J. H. Kim, “Good long-
term outcomes after surgical treatment of simple and complex
pulmonary aspergilloma,” Annals of Thoracic Surgery, vol. 79,
no. 1, pp. 294–298, 2005.
[ 2 7 ]J .G .A k b a r i ,P .K .V a r m a ,P .K .N e e m a ,M .U .M e n o n ,a n dK .
S. Neelakandhan, “Clinical proﬁle and surgical outcome for
pulmonary aspergilloma: a single center experience,” Annals
of Thoracic Surgery, vol. 80, no. 3, pp. 1067–1072, 2005.
[28] C. K. Park and S. Jheon, “Results of surgical treatment for
pulmonary aspergilloma,” European Journal of Cardio-thoracic
Surgery, vol. 21, no. 5, pp. 918–923, 2002.
[29] G. Babatasi, M. Massetti, A. Chapelier et al., “Surgical treat-
mentofpulmonaryaspergilloma:currentoutcome,”Journalof
Thoracic and Cardiovascular Surgery, vol. 119, no. 5, pp. 906–
912, 2000.
[30] J. F. Regnard, P. Icard, M. Nicolosi et al., “Apergilloma: a series
of 89 surgical cases,” Annals of Thoracic Surgery,v o l .6 9 ,n o .3 ,
pp. 898–903, 2000.
[31] Y. G. Kim, H. K. Yoon, G. Y. Ko, C. M. Lim, W. D. Kim, and
Y. Koh, “Long-term eﬀect of bronchial artery embolization in
Korean patients with haemoptysis,” Respirology, vol. 11, no. 6,
pp. 776–781, 2006.
[32] J.-Y. Chun and A.-M. Belli, “Immediate and long-term out-
comesofbronchialandnon-bronchialsystemicarteryemboli-
sation for the management of haemoptysis,” European Radiol-
ogy, vol. 20, no. 3, pp. 558–565, 2010.
[33] M. Jackson, C. D. R. Flower, and J. M. Shneerson, “Treatment
of symptomatic pulmonary aspergillomas with intracavitary
instillationofamphotericinBthroughanindwellingcatheter,”
Thorax, vol. 48, no. 9, pp. 928–930, 1993.
[34] K. S. Lee, H. T. Kim, Y. H. Kim, and K. O. Choe, “Treatment
of hemoptysis in patients with cavitary aspergilloma of the
lung: value of percutaneous instillation of amphotericin B,”
American Journal of Roentgenology, vol. 161, no. 4, pp. 727–
731, 1993.